

*Presented by:*

## **Therapeutic Radiology Grand Rounds – ASTRO Presentation Practice**

- 1. Oligometastatic Tumor Size as a Predictor of Distant Failure in Synchronous Oligometastatic NSCLC**
- 2. Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer**
- 3. Radioresistant Lung Oligometastatic and Oligoprogressive Lesions: Impact of Histology and Dose on Local Control**
- 4. Comparison of Diagnostic PET and 4D CT-Based Tumor Delineation for Oligometastatic Lung Tumors**

10/20/2022 9:00:00 AM–10/20/2022 10:00:00 AM | Medical Campus

Weekly grand rounds are necessary and essential to the educational mission of the department for trainees and faculty members to update them on the latest developments as well as a forum for discussion on the latest cases to promote group input.

**Texting code for today's session: 34770**

### **Faculty:**

Nicholas S Moore, MD, Patrick Oh, MD, Nipun Verma, MD & David Wallington, MD  
Residents, Yale New Haven Health

#### **Program Objective(s):**

- 1 Review oligometastatic disease paradigm and definition based on number of metastases; Discuss size of metastatic disease burden as a possible risk factor for new metastasis and next steps to evaluate metastatic disease volume as a possible risk factor.**
- 2 SBRT is an emerging modality for pancreatic cancer patients deemed to have borderline resectable or locally advanced disease; Significant heterogeneity in dose distribution may be evident between SBRT plans for pancreatic cancer. Dosimetric analysis of the Dmin, Dmax, and D90 for the GTV, ITV, and PTV can be useful to determine association with clinical outcomes, especially local control and Local control for pancreatic cancer can be significantly improved with a higher BED to the target volume.**
- 3 Treatment responses of radioresistant and non-radioresistant oligometastatic / oligoprogressive lung lesions; BED10 threshold to be used for treatment and histology of high risk radioresistant lung lesions and their response to radiation treatment.**
- 4 Describe the history of biologically guided radiation therapy, the principles of the Reflexion treatment delivery system using PET as a fiducial and the limitations of the PET-fiducial approach.**

**Target Audience:** Oncology

*Accreditation Statement: Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.*

*Nicholas Moore, MD, Patrick Oh, MD, Nipun Verma, MD, PhD and David Wallington, MD, faculty/planners for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies.*

*Gabrielle Peters MD, faculty planner for this educational event has no relevant financial relationship(s) to disclose with ineligible companies.*

*Designation Statement: Yale School of Medicine designates this Live Activity for a maximum of **1.00 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.*

**For questions, email [lisa.zucaro@yale.edu](mailto:lisa.zucaro@yale.edu)**